vs
Side-by-side financial comparison of American Express (AXP) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $18.9M, roughly 2.0× American Express). American Express runs the higher net margin — 15.7% vs -3.7%, a 19.4% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 11.4%). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -95.6%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
AXP vs GYRE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $37.2M |
| Net Profit | $3.0M | $-1.4M |
| Gross Margin | — | 95.3% |
| Operating Margin | — | 0.3% |
| Net Margin | 15.7% | -3.7% |
| Revenue YoY | 11.4% | 33.4% |
| Net Profit YoY | 15.0% | -340.1% |
| EPS (diluted) | — | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | $37.2M | ||
| Q3 25 | $10.4B | $30.6M | ||
| Q2 25 | $10.3B | $26.8M | ||
| Q1 25 | $9.6B | $22.1M | ||
| Q4 24 | $10.0B | $27.9M | ||
| Q3 24 | $9.7B | $25.5M | ||
| Q2 24 | $9.8B | $25.2M |
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | $-1.4M | ||
| Q3 25 | $2.9B | $5.9M | ||
| Q2 25 | $2.9B | $1.6M | ||
| Q1 25 | $2.6B | $3.7M | ||
| Q4 24 | $2.2B | $569.0K | ||
| Q3 24 | $2.5B | $2.9M | ||
| Q2 24 | $3.0B | $4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 95.3% | ||
| Q3 25 | — | 94.7% | ||
| Q2 25 | — | 95.7% | ||
| Q1 25 | — | 95.9% | ||
| Q4 24 | — | 95.8% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 96.9% |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | 0.3% | ||
| Q3 25 | 36.7% | 22.7% | ||
| Q2 25 | 34.4% | 8.1% | ||
| Q1 25 | 34.6% | 10.3% | ||
| Q4 24 | 27.7% | 2.4% | ||
| Q3 24 | 33.0% | 16.6% | ||
| Q2 24 | 38.6% | 12.7% |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | -3.7% | ||
| Q3 25 | 27.9% | 19.4% | ||
| Q2 25 | 28.0% | 5.9% | ||
| Q1 25 | 26.8% | 16.9% | ||
| Q4 24 | 21.8% | 2.0% | ||
| Q3 24 | 25.8% | 11.2% | ||
| Q2 24 | 30.7% | 18.0% |
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | $-0.01 | ||
| Q3 25 | $4.14 | $0.03 | ||
| Q2 25 | $4.08 | $0.00 | ||
| Q1 25 | $3.64 | $0.00 | ||
| Q4 24 | $3.04 | $0.00 | ||
| Q3 24 | $3.49 | $0.01 | ||
| Q2 24 | $4.15 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $52.4M |
| Total DebtLower is stronger | $60.4M | — |
| Stockholders' EquityBook value | $34.0M | $106.0M |
| Total Assets | $308.9M | $166.1M |
| Debt / EquityLower = less leverage | 1.78× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | $52.4M | ||
| Q3 25 | $1.3B | $60.0M | ||
| Q2 25 | $197.0M | $54.4M | ||
| Q1 25 | $261.0M | $29.9M | ||
| Q4 24 | $221.0M | $26.7M | ||
| Q3 24 | $120.0M | $25.1M | ||
| Q2 24 | $188.0M | $25.1M |
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | — | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | — | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | $106.0M | ||
| Q3 25 | $32.4B | $101.9M | ||
| Q2 25 | $32.3B | $92.0M | ||
| Q1 25 | $31.2B | $68.1M | ||
| Q4 24 | $30.3B | $63.3M | ||
| Q3 24 | $29.7B | $63.2M | ||
| Q2 24 | $29.5B | $60.4M |
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | $166.1M | ||
| Q3 25 | $297.6B | $159.4M | ||
| Q2 25 | $295.6B | $152.6M | ||
| Q1 25 | $282.2B | $129.8M | ||
| Q4 24 | $271.5B | $125.4M | ||
| Q3 24 | $271.0B | $125.2M | ||
| Q2 24 | $272.2B | $120.9M |
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | — | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-5.6M |
| Free Cash FlowOCF − Capex | — | $-5.8M |
| FCF MarginFCF / Revenue | — | -15.5% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $-5.6M | ||
| Q3 25 | $6.2B | $4.7M | ||
| Q2 25 | $4.4B | $2.1M | ||
| Q1 25 | $4.8B | $-129.0K | ||
| Q4 24 | $5.8B | $-2.8M | ||
| Q3 24 | $-1.8B | $1.7M | ||
| Q2 24 | $4.5B | $-5.5M |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | $-5.8M | ||
| Q3 25 | $5.6B | $4.0M | ||
| Q2 25 | $3.7B | $1.8M | ||
| Q1 25 | $4.3B | $-251.0K | ||
| Q4 24 | $5.3B | $-2.8M | ||
| Q3 24 | $-2.3B | $1.0M | ||
| Q2 24 | $4.0B | $-6.9M |
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | -15.5% | ||
| Q3 25 | 53.6% | 13.1% | ||
| Q2 25 | 36.3% | 6.8% | ||
| Q1 25 | 45.0% | -1.1% | ||
| Q4 24 | 53.1% | -10.1% | ||
| Q3 24 | -23.3% | 4.1% | ||
| Q2 24 | 40.4% | -27.5% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 0.4% | ||
| Q3 25 | 6.3% | 2.2% | ||
| Q2 25 | 6.0% | 1.0% | ||
| Q1 25 | 4.5% | 0.6% | ||
| Q4 24 | 5.0% | 0.2% | ||
| Q3 24 | 4.7% | 2.7% | ||
| Q2 24 | 5.8% | 5.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | 0.79× | ||
| Q2 25 | 1.51× | 1.32× | ||
| Q1 25 | 1.84× | -0.03× | ||
| Q4 24 | 2.66× | -4.85× | ||
| Q3 24 | -0.72× | 0.60× | ||
| Q2 24 | 1.50× | -1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
GYRE
Segment breakdown not available.
